Literature DB >> 13790538

Lymphangiomas of the ocular adnexa. An analysis of sixty-two cases.

I S JONES.   

Abstract

Entities:  

Keywords:  CONJUNCTIVA/neoplasms; EYELIDS/neoplasms; LYMPHANGIOMA/case reports

Mesh：

Year:  1961        PMID： 13790538     DOI： 10.1016/0002-9394(61)92094-3

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN： 0002-9394            Impact factor:   5.258


× No keyword cloud information.
  7 in total

1.  Management of orbital lymphangioma using intralesional injection of OK-432.

Authors:  Y Suzuki; A Obana; Y Gohto; T Miki; H Otuka; Y Inoue
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

2.  Orbital lymphangioma treated by lateral wall decompression and fat removal.

Authors:  Jeong Kyu Lee; Tae Soo Lee
Journal:  Jpn J Ophthalmol       Date:  2010-04-18       Impact factor: 2.447

3.  Results of Intralesional Bleomycin Sclerotherapy for Treatment of Orbital Lymphangiomas at a Tertiary Eye Care Centre in Bangladesh.

Authors:  Murtuza Nuruddin; Soma Rani Roy; Hardeep Singh Mudhar
Journal:  Ocul Oncol Pathol       Date:  2019-03-12

4.  Orbital lymphangioma: an analysis of 26 patients.

Authors:  M Tunç; E Sadri; D H Char
Journal:  Br J Ophthalmol       Date:  1999-01       Impact factor: 4.638

5.  Resection of an orbital lymphangioma with the aid of an intralesional liquid polymer.

Authors:  Amit D Malhotra; Mona Parikh; Daniel C Garibaldi; Shannath L Merbs; Neil R Miller; Kieran Murphy
Journal:  AJNR Am J Neuroradiol       Date:  2005 Nov-Dec       Impact factor: 3.825

6.  Intracranial vascular anomalies in patients with periorbital lymphatic and lymphaticovenous malformations.

Authors:  A Bisdorff; J B Mulliken; J Carrico; R L Robertson; P E Burrows
Journal:  AJNR Am J Neuroradiol       Date:  2007-02       Impact factor: 3.825

7.  Sclerosing therapy for orbital lymphangioma using sodium tetradecyl sulfate.

Authors:  Anuchit Poonyathalang; Pisit Preechawat; Pakorn Jiarakongmun; Sirintara Pongpech
Journal:  Jpn J Ophthalmol       Date:  2008-09-05       Impact factor: 2.447
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.